Default company panoramic image

CerMed Corporation

Innovative Diagnostics for a Healthier World

  • Stage Full Product Ready
  • Industry Medical Devices and Equipment
  • Location Sunnyvale, CA, USA
  • Currency USD
  • Founded November 2008
  • Employees 11
  • Website

Company Summary

CerMed Corporation is a Medical Device Company founded in 2008. Our initial strategy is to fill a glaring need in the screening and diagnosis of Cervical Cancer. CerMed offers a fully automated, multiplex capable, bio‐molecular platform and biomarkers, which can quantitatively screen for disease and disease progression providing higher sensitivity/specificity at a lower cost as compared to the current gold standard...the 65 year old Pap smear.


  • Default avatar
    Peter P. Gombrich
    Chief Executive Officer, Board Chairman, Founder

    Peter Gombrich is a serial entrepreneur having successfully founded three medical device companies. Under his leadership, he rose over $200 million and took several companies public. Peter founded CerMed in 2008, and has been working in the field of molecular diagnostics for women’s health for nearly 10 years. Prior to founding CerMed, he founded Diamics, a women’s healthcare company focused on cervical cancer screening. From 1992 to 2006, Peter

  • Default avatar
    Irene Podolak
    President CerMed International, Board Director

    Irene Podolak has over 30 years of very broad experience in the health industry including positions in community based hospitals, large national healthcare consulting firms, an international information systems vendor, and a national health database corporation. She is a former Partner from the National Health Services Practice at Deloitte & Touche, where she was the founder and leader of the practice for over 10 years. Irene has had extensive co

  • Default avatar
    Scott Christensen
    President and Chief Operating Officer

    Scott Christensen brings almost 35 years of medical device and early stage business development to CerMed. With a functional background in Marketing and Sales, he brings deep experience in developing and launching disruptive new technologies to the global marketplace. Most recently, Scott served as President and CEO of venture backed Dynatherm Medical, which was successfully acquired by a strategic partner in 2012. Prior to Dynatherm, Scott serv

  • Default avatar
    Paul Vichi
    Chief Molecular Scientist

    Dr. Paul Vichi has over 15 years of research and development experience in oncology focused molecular biology and clinical microbiology, with previous faculty appointments in the departments of Biomedical Technology and Pathology at the University of Vermont, as well as senior positions for commercial R&D. Dr. Vichi joined CerMed in 2008, and is responsible for development of CerMed’s molecular Screening products. From 2005 – 2008, he was Senior

  • Default avatar
    Linda Oleson
    Vice-President Medical & Clinical Affairs

    Linda Oleson has over 20 years of experience including execution and management of pre-clinical/clinical activities, product training for medical device startup companies and regulatory. She has provided consulting services through the full life cycle for numerous companies from inception through to acquisition and closure and has also lobbied successfully on legislation that supports entrepreneurs. In addition, Linda has worked with medical cons

  • Default avatar
    Alan Jernigan
    Vice-President, International Sales and Marketing

    20+ years of worldwide sales and marketing experience in the diagnostics, life sciences and biotech industry including specific experience in women’s health and infectious diseases. He has previous experience at Abbott Diagnostics, Igen (Roche) as well as a number of early stage companies. Alan holds an MBA from Oklahoma City University and a Bachelor of Science in Business Administration from Oklahoma State University.

  • Default avatar
    Nam Kim
    Senior Director Biochemistry

    Dr. Nam Kim is and experienced research and development scientist and manager with a track record of successfully implementing and executing development projects. He has over 20 years of experience in the pharma/biotech industry with expertise in the development of novel biomarkers and diagnostic tests. Dr. Kim holds a Ph.D. in Microbiology from the University of Toronto, Canada, an M.Sc. in Microbiology from the University of Toronto and a B.Sc.